Difference between revisions of "Part:BBa K3142005:Design"

Latest revision as of 22:09, 20 October 2019

Antihypertensive dipeptide（VY）

Assembly Compatibility:

10
COMPATIBLE WITH RFC[10]
12
COMPATIBLE WITH RFC[12]
21
COMPATIBLE WITH RFC[21]
23
COMPATIBLE WITH RFC[23]
25
COMPATIBLE WITH RFC[25]
1000
COMPATIBLE WITH RFC[1000]

Design Notes

The sequence has been optimized for lactic acid bacteria. It is a small molecule bioactive peptide that is difficult to directly biosynthesize. Therefore, the fusion expression strategy is currently used.

Source

no

References

Martin, M, A. Wellner, I. Ossowski, and T. Henle. Identification and quantification of inhibitors for Angiotensin-converting enzyme in hypoallergenic infant milk formulas.[J] Agric Food Chem. 2006,56:6333–6338.

Revision as of 22:09, 20 October 2019 (view source) Xiaolin (Talk \| contribs) (→‎Design Notes) ← Older edit		Latest revision as of 22:09, 20 October 2019 (view source) Xiaolin (Talk \| contribs) (→‎References)
Line 14:		Line 14:

	===References===		===References===
		+
		+	Martin, M, A. Wellner, I. Ossowski, and T. Henle. Identification and quantification of inhibitors for Angiotensin-converting enzyme in hypoallergenic infant milk formulas.[J] Agric Food Chem. 2006,56:6333–6338.